<p>Ascletis Pharma Inc. has announced the selection of ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, as a clinical development candidate for the treatment of obesity and other cardio-metabolic diseases. In head-to-head non-human primate studies, ASC37 demonstrated an average observed half-life of approximately 17 days—seven times longer than retatrutide—supporting its potential as a once-monthly subcutaneous treatment. In vitro studies showed ASC37 to be 5-, 4-, and 4-fold more potent for GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. FDA for ASC37 injection in the second quarter of 2026. These research results have been announced by the company, but have not yet been presented at a scientific meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN66622) on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>Ascletis Pharma Inc. has selected ASC37 injection, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development targeting obesity and cardio-metabolic diseases. In studies, ASC37 showed a half-life of about 17 days, making it a potential once-monthly treatment. It was found to be significantly more potent than retatrutide. The company plans to submit an Investigational New Drug Application to the U.S. FDA in Q2 2026. This announcement has not yet been presented at a scientific meeting.</p>

Reuters

Health Care Select Sector SPDR

Yinhua CSI Innovative Drugs Industry ETF

Proshares UltraShort Nasdaq Biotech

ALPS Medical Breakthrough

iShares US Pharma

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

VG Health

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

SPDR S&P Biotech

E Fund CSI 300 Health Care ETF

Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment